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Abstract
Background: Osteogenesis imperfecta (OI) is a collagen-related bone dysplasia leading to a susceptibility to fractures.
OI can be caused by mutations in several genes including BMP1. It encodes two isoforms, bone morphogenetic
protein 1 (BMP1) and mammalian tolloid (mTLD); both have proteolytic activity to remove the C-propeptide from
procollagen.
Case presentation: We report a Thai OI patient who had his first fracture at the age of three months. Using next
generation sequencing, we successfully identified two novel compound heterozygous BMP1 mutations. One mutation,
c.796_797delTT (p.Phe266Argfs*25) affects both BMP1 and mTLD isoforms, while the other, c.2108-2A > G, affects only
the BMP1 isoform. Preservation of the mTLD may explain the relatively less severe clinical phenotype in this patient.
Intravenous bisphosphonate was given from the age of 8 months to 5 years. He was free from fractures for 9 months
before discontinuation.
Conclusion: This case expands the mutation spectrum of BMP1, strengthens the correlation between genotype and
phenotype, and supports the benefits of bisphosphonate in OI patients with BMP1 mutations.
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Background
Osteogenesis imperfecta (OI), a brittle bone disease, is a
collagen-related bone dysplasia characterized by bone
fragility leading to a susceptibility to fractures. Clinical
manifestations of OI vary from intrauterine fractures
and perinatal death to a mild form with few or no frac-
tures [1]. Other features include short stature, bone
deformities, joint laxity, dentinogenesis imperfecta, and
blue sclerae. OI has been classified into autosomal dom-
inant and recessive forms. More than 90% of OI patients
are caused by mutations in COL1A1 (Collagen Type I
Alpha Chain) and COL1A2 (Collagen Type II Alpha
Chain), inherited in an autosomal dominant manner.
COL1A1 and COL1A2 encode alpha 1 and alpha 2
chains of type I collagen, respectively. Other inherited
forms are rare and can be caused by mutations in differ-
ent genes including IFITM5 (Interferon Induced Trans-
membrane Protein 5) responsible for a dominant form,
14 genes for the recessive form, BMP1 (Bone Morpho-
genic Protein 1), CRTAP (Cartilage Associated Protein),
CREB3L1 (CAMP Responsive Element Binding Protein 3
Like 1), FKBP10 (FKP506 Binding Protein 10), LEPRE1
(Leucine- And Proline-Enriched Proteoglycan 1), PLOD2
(Procollagen-Lysine, 2 –Oxoglutarate 5-Dioxygenase 2),
PPIB (Peptidylprolyl Isomerase B), SEC24D (SEC24
Homolog A, COPII Coat Complex Component), SER-
PINF1 (Serpin Family F Member 1), SERPINH1 (Serpin
Family H Member 1), SP7 (Sp7 Transcription Factor),
SPARC (Secreted Protein Acidic And Cysteine Rich),
TMEM38B (Transmembrane Protein 38B) and WNT1
(Wnt Family Member 1) [2–4] and MBTPS2 (Membrane
Bound Transcription Factor Peptidase, Site 2) for the X-
linked form [5].
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Mutations in COL1A1 and COL1A2 result in primary
structural or quantitative defects of type I collagen. The
recessive forms of OI arise from defects in proteins that
are responsible for post-translation modification of colla-
gen, including defects in proteins responsible for folding
and processing of collagen, and from defects in proteins
that are necessary for ossification, mineralization or
osteoblast development.
Proα1 and proα2 chains of type I collagen are post-
translationally modified in the endoplasmic reticulum
lumen into triple helix and then secreted into the extra-
cellular matrix. After cleavage of their N and C-terminal
propeptides, trimeric collagen molecules will be ar-
ranged into highly ordered collagen fibrils. BMP1, which
is located on chromosome 8p21.3, encodes a protein
with a role in proteolytic removal of the C-propeptide
from procollagen. This crucial step is needed for the assem-
bly of mature collagen monomers into fibrils [6]. Here we
describe a Thai boy with OI who harbored two novel com-
pound heterozygous BMP1 mutations, c.796_797delTT
(p.Phe266Argfs*25) and c.2108-2A >G.
Case presentation
Our patient was a 6-year-old boy, who was the second
child of a non-consanguineous Thai couple. There was
no family history of OI or other bone disorders. He was
born at term with a birth weight of 3600 g (60th centile).
His early development was normal. He sustained the
first fracture of his right arm at the age of three months
from a minor trauma. Since then he had multiple frac-
tures of various bones including both humeri, femora,
tibiae, ulnae and radii, leading to a diagnosis of OI
Sillence type III. Intravenous bisphosphonate was initi-
ated at the age of 8 months; however, the fractures
continued to occur once every few months and required
many surgeries. At the age of 5 years, after he was free
from fractures for 9 months, bisphosphonate was dis-
continued. His mental development was appropriate. He
was able to walk until the age of six years, when a non-
union and muscle wasting of lower extremities occurred.
Physical examination revealed deformities of both upper
and lower extremities. However, no blue sclerae or den-
tinogenesis imperfecta was observed. Investigations re-
vealed normal serum calcium, phosphorus and alkaline
phosphatase levels. Plain radiographs of his long bones
at the age of nine are shown in Fig. 1.
After informed consent was obtained, genomic DNA
was extracted from leukocytes using a Puregene blood
kit (Qiagen, Hilden, Germany). Sixteen known OI genes,
BMP1, COL1A1, COL1A2, CREB3L1, CRTAP, FKBP10,
IFITM5, LEPRE1, PLOD2, PPIB, SERPINF1, SERPINH1,
SP7, TMEM38B, WNT1, and MBTPS2, were amplified
from 200 ng of genomic DNA using the Truseq Ampli-
con Sequencing kit (Illumina, San Diego, CA). 286
amplicons which covered all the 226 exons (28 kb) of
the target genes were sequenced by Miseq (Illumina, San
Diego, CA) using 2x250 paired-end reads. All reads were
aligned against the University of California Santa Cruz
human genome assembly hg19 using Burrows-Wheeler
Alignment software [7]. SNVs and Indel were detected by
Miseq reporter software. Finally, possible disease causing
variants were confirmed by PCR and Sanger sequencing.
Segregation analysis was subsequently performed.
The targeted gene panel study using next generation
sequencing of the proband revealed compound heterozy-
gous mutations, c.796_797delTT (p.Phe266Argfs*25)
and c.2108-2A > G in the BMP1 gene (NM_006129.4).
PCR followed by Sanger sequencing using genomic
Fig. 1 AP plain radiographs of lower extremities at the age of nine. a Both femoral AP radiographs reveal a nonunion at the shaft with shortening and
varus deformity of the left femur. Intramedullary rods were used to stabilize the fractures. Generalized osteopenia is noted. b Both tibial AP radiographs
reveal a nonunion, varus deformity, and shortening of the right tibia. Intramedullary rods were used to stabilize the fractures
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DNA of leukocytes from the patient and his parents
confirmed that the patient was compound heterozygous
for the mutations, while his father had c.796_797delTT
(p. Phe266Argfs*25) and his mother had c.2108-2A > G
(Fig. 2). Both mutations have never been previously de-
scribed in Human Gene Mutation Database [8] or the
Exome Aggregation Consortium database [9].
Discussion
We identified a Thai patient with OI who had his
first fracture at the age of three months. He was
found to be compound heterozygous for c.796_797delTT
(p. Phe266Argfs*25) and c.2108-2A >G mutations in the
BMP1 gene (Fig. 2). Both have never been reported. Add-
ing this patient to the literature, there are currently 15 pa-
tients from 12 families (Table 1) who have an autosomal
recessive form of OI resulted from mutations in the
BMP1gene. Eight patients of six families were homozy-
gous while the other seven patients of six families were
compound heterozygous. Of these 12 families, 12 different
mutations have been identified (Fig. 3).
Processing of procollagen I C-terminal propeptide
(PICP) is accomplished byfour BMP1-like proteinases:
BMP1, mammalian tolloid (mTLD), and mammalian
tolloid-like 1 and 2 (mTLL1 and 2). BMP1 and mTLD
are resulted from the alternative splicing of the BMP
gene, which is located on chromosome 8p21.3. The
other two remaining members of this protein family,
mTLL1 and mTLL2, are encoded by Tll1 and Tll2 lo-
cated on chromosome 4q32.3 and 10q24.1, respectively.
BMP1 has the highest PICP cleavage efficiency in vitro,
followed by mTLD and mTLL1, while mTLL2 has no
cleavage activity [10].
Of all the 12 BMP1 mutations identified to date, nine
affect both BMP1 and mTLD while the other three:
c.2108-2A > G, Gln730Prof*294, and c*241 T > C affect
only the BMP1 (Fig. 3). No mutations have been found
in positions affecting only the mTLD. Those mutant
alleles affecting only the BMP1 are expected to synthesize
an intact mTLD, which has some PICP activity leading to a
relatively milder form of OI. This hypothesis is true
for the 11 families except Family 11 of Table 1, which
harbored the c.34G > C (p.Gly12Arg) and c.2188dupC
(p.Gln730Profs*294) mutations. Although the latter
mutation affects only BMP1, two siblings of this fam-
ily had severe bone fragility with more than a hun-
dred fractures [11].
The conditions of the eight patients with both mutant
alleles affecting both isoforms, no matter they are homo-
zygous (Families 1, 2, and 3 of Table 1) or compound
heterozygous (Families 8, 9, and 10 of Table 1), are rela-
tively more severe. They had high frequency of fractures
and severe bone deformities. For instance, the two pa-
tients with homozygous p.Phe249Leu mutation (Family
1 of Table 1), which is in the enzymatically active astacin
domain affecting both BMP1 and mTLD, had very se-
vere clinical presentation including severe bone fragility
with fracture rate at 10-15/year, decreased bone mass,
bone deformities, marked short stature and dysmorphic
facial features.
Patients who were compound heterozygous with one
mutant allele affecting only the BMP1 resulting in an in-
tact mTLD (Families 7, 11, and 12 of Table 1) had rela-
tively milder phenotypes. Our patient was compound
heterozygous. One mutation, c.796_797delTT (p.
Phe266Argfs*25) is an out-of-frame deletion in the asta-
cin domain affecting both BMP1 and mTLD isoforms.
The other mutation, c.2108-2A > G, is predicted to affect
only the BMP1 isoform but preserve the mTLD (Fig. 3).
This may explain the milder disease severity of our pa-
tient who had his first fracture at the age of three
months, compared with patients whose mutations affect
both BMP1 and mTLD.
Three patients (Families 4, 5, and 6 of Table 1) were
homozygous for the c.*241 T > C. This mutation is pre-
dicted to affect only the BMP1 and preserve the activity
Fig. 2 Mutation analysis. Direct sequencing shows that the proband is compound heterozygous for c.796_797delTT (p.Phe266Argfs*25) and c.2108-2A >G
in the BMP1 gene (NM_006129.4) while his father had c.796_797delTT (p. Phe266Argfs*25) and his mother had c.2108-2A >G
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of mTLD. They had the mildest phenotype. Their total
number of fractures was 12, 16, and 18 times at the ages
of 17, 22, and 28, respectively. In addition, two of them
had the latest onset of the first fracture, which occurred
at the ages of 2.5 and 4 years. Compared with a
Canadian-French patient with compound heterozygous
mutations, c.*241 T > C and p.Glu703Gln (Family 7 of
Table 1) who had first fracture at birth and 12 total frac-
tures at the age of eight, the three patients with homozy-
gous c.*241 T > C had a later onset and lower rates of
fractures. This finding could be explained by the fact
that the p.Glu703Gln mutation in Family 7 affects the
activity of both BMP1 and mTLD.
Interestingly, most of the OI patients with BMP1 mu-
tations have increased or normal bone mineral density
(BMD), which is unusual for OI. Despite an increased
BMD, some patients received bisphosphonate. After the
treatment with bisphosphonate, two siblings with homo-
zygous p.Gly12Arg had an increased BMD, an elevated
urinary deoxypyridinoline excretion (a marker for osteo-
clastic activities) and a reduced fracture rate [12]. Intra-
venous bisphosphonate therapy in two Canadian-French
patients (Families 6 and 7 of Table 1) with an elevated
BMD also exhibited a similar result. One of them
showed improvement in the shape of compressed verte-
bral bodies and a reduction in fracture rate [13]. Our




1 2 Homozygous c.747C > G (p.Phe249Leu) [14]
2 2 Homozygous c.34G > C (p.Gly12Arg) [12]
3 1 Homozygous c.34G > C (p.Gly12Arg) [15]
4 1 Homozygous c.*241 T > C [13]
5 1 Homozygous c.*241 T > C
6 1 Homozygous c.*241 T > C
7 1 Heterozygous c.*241 T > C; c.2107G > C (p.Glu703Gln)
8 1 Heterozygous c. 808A > G (p.Met270Val); c.1297G > T* [16]
9 1 Heterozygous c.925delG (p.Asp309Thrfs*54); c.1492G > A (p.Gly498Arg) [11]
10 1 Heterozygous c.34G > C (p.Gly12Arg); c.1839delC (p.Asn614Thrfs*188)
11 2 Heterozygous c.34G > C (p.Gly12Arg); c.2188dupC (p.Gln730Profs*294)
12 1 Heterozygous c.796_797delTT (p.Phe266Argfs*25); c.2108-2A > G This report
*This variant caused exon 10 skipping
Fig. 3 Map of the mutations in BMP1 and mTLD. Mutations shown between the two isoforms affect both BMP1 and mTLD, while those shown
above BMP1 affect only BMP1. The mutations found in our patient are bolded. The underlined mutation is considered to cause exon 10 skipping
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patient was also given intravenous bisphosphonate and a
decrease in fracture frequency was observed. Unfortu-
nately, he did not undergo a BMD measurement. Whether
bisphosphonate therapy in OI patients with BMP1 muta-
tions is useful awaits further studies.
Conclusion
We described an OI patient with two novel compound
heterozygous mutations in BMP1. One of the two is ex-
pected to preserve the mTLD isoform, which may lead
to his relatively mild phenotype.
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